BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 15496679)

  • 1. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.
    Fleming SM; Salcedo J; Fernagut PO; Rockenstein E; Masliah E; Levine MS; Chesselet MF
    J Neurosci; 2004 Oct; 24(42):9434-40. PubMed ID: 15496679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exacerbation of sensorimotor dysfunction in mice deficient in Atp13a2 and overexpressing human wildtype alpha-synuclein.
    Dirr ER; Ekhator OR; Blackwood R; Holden JG; Masliah E; Schultheis PJ; Fleming SM
    Behav Brain Res; 2018 May; 343():41-49. PubMed ID: 29407413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.
    Richter F; Subramaniam SR; Magen I; Lee P; Hayes J; Attar A; Zhu C; Franich NR; Bove N; De La Rosa K; Kwong J; Klärner FG; Schrader T; Chesselet MF; Bitan G
    Neurotherapeutics; 2017 Oct; 14(4):1107-1119. PubMed ID: 28585223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence of aggregate formation.
    Gispert S; Del Turco D; Garrett L; Chen A; Bernard DJ; Hamm-Clement J; Korf HW; Deller T; Braak H; Auburger G; Nussbaum RL
    Mol Cell Neurosci; 2003 Oct; 24(2):419-29. PubMed ID: 14572463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.
    Richfield EK; Thiruchelvam MJ; Cory-Slechta DA; Wuertzer C; Gainetdinov RR; Caron MG; Di Monte DA; Federoff HJ
    Exp Neurol; 2002 May; 175(1):35-48. PubMed ID: 12009758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel adaptive rotating beam test unmasks sensorimotor impairments in a transgenic mouse model of Parkinson's disease.
    Gerstenberger J; Bauer A; Helmschrodt C; Richter A; Richter F
    Behav Brain Res; 2016 May; 304():102-10. PubMed ID: 26880341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.
    Masliah E; Rockenstein E; Veinbergs I; Mallory M; Hashimoto M; Takeda A; Sagara Y; Sisk A; Mucke L
    Science; 2000 Feb; 287(5456):1265-9. PubMed ID: 10678833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-synuclein and transgenic mouse models.
    Fernagut PO; Chesselet MF
    Neurobiol Dis; 2004 Nov; 17(2):123-30. PubMed ID: 15474350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
    Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
    BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration.
    Manning-Bog AB; McCormack AL; Purisai MG; Bolin LM; Di Monte DA
    J Neurosci; 2003 Apr; 23(8):3095-9. PubMed ID: 12716914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.
    Rockenstein E; Mallory M; Hashimoto M; Song D; Shults CW; Lang I; Masliah E
    J Neurosci Res; 2002 Jun; 68(5):568-78. PubMed ID: 12111846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein.
    Lakso M; Vartiainen S; Moilanen AM; Sirviö J; Thomas JH; Nass R; Blakely RD; Wong G
    J Neurochem; 2003 Jul; 86(1):165-72. PubMed ID: 12807436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
    Fleming SM; Salcedo J; Hutson CB; Rockenstein E; Masliah E; Levine MS; Chesselet MF
    Neuroscience; 2006 Nov; 142(4):1245-53. PubMed ID: 16934409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein mice.
    Ekmark-Lewén S; Lindström V; Gumucio A; Ihse E; Behere A; Kahle PJ; Nordström E; Eriksson M; Erlandsson A; Bergström J; Ingelsson M
    Brain Behav; 2018 Mar; 8(3):e00915. PubMed ID: 29541535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
    Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
    Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice.
    Rathke-Hartlieb S; Kahle PJ; Neumann M; Ozmen L; Haid S; Okochi M; Haass C; Schulz JB
    J Neurochem; 2001 May; 77(4):1181-4. PubMed ID: 11359883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treadmill exercise intervention improves gait and postural control in alpha-synuclein mouse models without inducing cerebral autophagy.
    Minakaki G; Canneva F; Chevessier F; Bode F; Menges S; Timotius IK; Kalinichenko LS; Meixner H; Müller CP; Eskofier BM; Casadei N; Riess O; Schröder R; Winkler J; Xiang W; von Hörsten S; Klucken J
    Behav Brain Res; 2019 May; 363():199-215. PubMed ID: 30599154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Viral-mediated oligodendroglial alpha-synuclein expression models multiple system atrophy.
    Bassil F; Guerin PA; Dutheil N; Li Q; Klugmann M; Meissner WG; Bezard E; Fernagut PO
    Mov Disord; 2017 Aug; 32(8):1230-1239. PubMed ID: 28556404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
    Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
    Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.